HRP20160126T1 - Kristalinični oblici 3-(2,6-diklor-3,5-dimetoksi-fenil)-1-{6-[4-(4-etilpiperazin-1-il)-fenilamino]-pirimidin-4-il}-1-metil-ureje i njihove soli - Google Patents
Kristalinični oblici 3-(2,6-diklor-3,5-dimetoksi-fenil)-1-{6-[4-(4-etilpiperazin-1-il)-fenilamino]-pirimidin-4-il}-1-metil-ureje i njihove soliInfo
- Publication number
- HRP20160126T1 HRP20160126T1 HRP20160126T HRP20160126T HRP20160126T1 HR P20160126 T1 HRP20160126 T1 HR P20160126T1 HR P20160126 T HRP20160126 T HR P20160126T HR P20160126 T HRP20160126 T HR P20160126T HR P20160126 T1 HRP20160126 T1 HR P20160126T1
- Authority
- HR
- Croatia
- Prior art keywords
- methyles
- ethylpiperazin
- phenylamino
- pyrimidin
- dimethoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26715509P | 2009-12-07 | 2009-12-07 | |
| PCT/US2010/059108 WO2011071821A1 (en) | 2009-12-07 | 2010-12-06 | Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof. |
| EP10788479.3A EP2509963B1 (en) | 2009-12-07 | 2010-12-06 | Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20160126T1 true HRP20160126T1 (hr) | 2016-03-25 |
Family
ID=43983750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160126T HRP20160126T1 (hr) | 2009-12-07 | 2010-12-06 | Kristalinični oblici 3-(2,6-diklor-3,5-dimetoksi-fenil)-1-{6-[4-(4-etilpiperazin-1-il)-fenilamino]-pirimidin-4-il}-1-metil-ureje i njihove soli |
Country Status (32)
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0512324D0 (en) * | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| AR079257A1 (es) * | 2009-12-07 | 2012-01-04 | Novartis Ag | Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| WO2013144339A1 (en) * | 2012-03-30 | 2013-10-03 | Novartis Ag | Fgfr inhibitor for use in the treatment of hypophosphatemic disorders |
| SI2861595T1 (sl) | 2012-06-13 | 2017-04-26 | Incyte Holdings Corporation | Substituirane triciklične spojine kot inhibitorji fgfr |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| AR094812A1 (es) | 2013-02-20 | 2015-08-26 | Eisai R&D Man Co Ltd | Derivado de piridina monocíclico como inhibidor del fgfr |
| TWI647220B (zh) | 2013-03-15 | 2019-01-11 | 美商西建卡爾有限責任公司 | 雜芳基化合物及其用途 |
| US9663524B2 (en) | 2013-03-15 | 2017-05-30 | Celgene Car Llc | Substituted pyrido[2,3-d]pyrimidines as protein kinase inhibitors |
| UA120248C2 (uk) | 2013-03-15 | 2019-11-11 | Селджен Кар Ллс | Гетероарильні сполуки та їх застосування |
| WO2014155268A2 (en) | 2013-03-25 | 2014-10-02 | Novartis Ag | Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity |
| LT2986610T (lt) | 2013-04-19 | 2018-04-10 | Incyte Holdings Corporation | Bicikliniai heterociklai, kaip fgfr inhibitoriai |
| CA2917667A1 (en) * | 2013-07-09 | 2015-01-15 | Dana-Farber Cancer Institute, Inc. | Kinase inhibitors for the treatment of disease |
| CA2924206C (en) * | 2013-10-18 | 2022-10-25 | Eisai R&D Management Co., Ltd. | Pyrimidine fgfr4 inhibitors |
| SG10202104627UA (en) | 2013-12-13 | 2021-06-29 | Novartis Ag | Pharmaceutical dosage forms |
| MX369646B (es) | 2014-08-18 | 2019-11-15 | Eisai R&D Man Co Ltd | Sal de derivado de piridina monociclico y su cristal. |
| WO2016055916A1 (en) | 2014-10-06 | 2016-04-14 | Novartis Ag | Therapeutic combination for the treatment of cancer |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| SG10201913036RA (en) | 2015-02-20 | 2020-02-27 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| CN107787226A (zh) * | 2015-03-25 | 2018-03-09 | 诺华股份有限公司 | 药物组合 |
| WO2016152907A1 (ja) | 2015-03-25 | 2016-09-29 | 国立研究開発法人国立がん研究センター | 胆管癌治療剤 |
| EP3283465B1 (en) | 2015-04-14 | 2021-01-06 | Eisai R&D Management Co., Ltd. | Crystalline fgfr4 inhibitor compound and uses thereof |
| CN104803925B (zh) * | 2015-04-16 | 2018-01-12 | 温州医科大学 | 一类以fgfr为靶点的2，4，5‑三取代嘧啶类化合物及其制备方法和用途 |
| WO2016189472A1 (en) | 2015-05-28 | 2016-12-01 | Novartis Ag | Fgfr inhibitor for use in the treatment of the phosphaturic mesenchymal tumor |
| CN108367000A (zh) | 2015-12-17 | 2018-08-03 | 卫材R&D管理有限公司 | 用于乳腺癌的治疗剂 |
| WO2017196854A1 (en) | 2016-05-10 | 2017-11-16 | Eisai R&D Management Co., Ltd. | Drug combinations for reducing cell viability and/or cell proliferation |
| CN108884097B (zh) * | 2016-05-20 | 2021-05-28 | 浙江海正药业股份有限公司 | 嘧啶类衍生物、其制备方法和其在医药上的用途 |
| KR102466192B1 (ko) * | 2016-08-23 | 2022-11-14 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 간세포성 암종의 치료를 위한 조합 요법 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| CN107176954B (zh) | 2017-06-02 | 2019-01-11 | 无锡双良生物科技有限公司 | 一种egfr抑制剂的药用盐及其晶型、制备方法和应用 |
| AU2018361264B2 (en) * | 2017-11-01 | 2021-04-01 | Guangdong Xianqiang Pharmaceutical Co., Ltd | Salt form and crystal form of compound as FGFR4 inhibitor and preparation method thereof |
| WO2019189241A1 (ja) | 2018-03-28 | 2019-10-03 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 肝細胞癌治療剤 |
| PL3788047T3 (pl) | 2018-05-04 | 2025-04-14 | Incyte Corporation | Stałe postacie inhibitora fgfr i sposoby ich otrzymywania |
| KR20210018264A (ko) | 2018-05-04 | 2021-02-17 | 인사이트 코포레이션 | Fgfr 억제제의 염 |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CR20220169A (es) | 2019-10-14 | 2022-10-27 | Incyte Corp | Heterociclos bicíclicos como inhibidores de fgfr |
| CN119462616A (zh) * | 2019-10-14 | 2025-02-18 | 和记黄埔医药（上海）有限公司 | 化合物的盐及其晶型 |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| AU2020395185A1 (en) | 2019-12-04 | 2022-06-02 | Incyte Corporation | Derivatives of an FGFR inhibitor |
| JP7720840B2 (ja) | 2019-12-04 | 2025-08-08 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式複素環 |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| EP4352060A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
| WO2022271933A1 (en) | 2021-06-23 | 2022-12-29 | Kimtron, Inc. | System and method for ultra-close proximity irradiation of rotating biomass |
| AU2023236231A1 (en) * | 2022-03-18 | 2024-09-05 | Shanghai Institute Of Materia Medica , Chinese Academy Of Sciences | Salt of substituted amino six-membered nitric heterocyclic compound, crystal form thereof, method for preparing same, and use thereof |
| CN115785001B (zh) * | 2022-11-23 | 2023-09-15 | 斯坦德药典标准物质研发(湖北)有限公司 | 一种英菲格拉替尼的制备方法 |
| WO2024186882A1 (en) | 2023-03-06 | 2024-09-12 | Qed Therapeutics, Inc. | Methods of treating skeletal dysplasias |
| WO2025061013A1 (zh) * | 2023-09-18 | 2025-03-27 | 上海润石医药科技有限公司 | 包含杂芳基氧基萘类化合物的药物组合物及其制备方法和应用 |
| WO2025090870A1 (en) | 2023-10-27 | 2025-05-01 | Qed Therapeutics, Inc. | Infigratinib and metabolites thereof for use in methods of treating skeletal disorders |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0512324D0 (en) * | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| CN101242843A (zh) * | 2005-06-10 | 2008-08-13 | 詹森药业有限公司 | 作为激酶调节剂的氨基嘧啶类化合物 |
| AU2006311433B2 (en) * | 2005-11-08 | 2012-06-28 | Choongwae Pharma Corporation | Alpha-helix mimetics and method relating to the treatment of cancer stem cells |
| MEP3808A (xx) * | 2005-12-21 | 2010-02-10 | Novartis Ag | Derivati pirimidinil aril uree kao fgf inhibitori |
| MX342553B (es) * | 2008-04-29 | 2016-10-04 | Novartis Ag | Metodos para monitorear la modulacion de la actividad de cinasa del receptor del factor de crecimiento de fibroblastos y uso de dichos metodos. |
| AR079257A1 (es) * | 2009-12-07 | 2012-01-04 | Novartis Ag | Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas |
-
2010
- 2010-12-03 AR ARP100104472A patent/AR079257A1/es not_active Application Discontinuation
- 2010-12-05 JO JOP/2010/0433A patent/JO3061B1/ar active
- 2010-12-06 RU RU2012128351/04A patent/RU2572848C2/ru active
- 2010-12-06 KR KR1020127017618A patent/KR101787784B1/ko active Active
- 2010-12-06 CN CN201510484635.8A patent/CN105061332A/zh active Pending
- 2010-12-06 ES ES10788479.3T patent/ES2562462T3/es active Active
- 2010-12-06 NZ NZ700778A patent/NZ700778A/en unknown
- 2010-12-06 AU AU2010328391A patent/AU2010328391B2/en active Active
- 2010-12-06 EP EP10788479.3A patent/EP2509963B1/en active Active
- 2010-12-06 MY MYPI2012002222A patent/MY158333A/en unknown
- 2010-12-06 CN CN201911278014.9A patent/CN111269186A/zh active Pending
- 2010-12-06 HR HRP20160126T patent/HRP20160126T1/hr unknown
- 2010-12-06 MX MX2012006562A patent/MX2012006562A/es active IP Right Grant
- 2010-12-06 NZ NZ624315A patent/NZ624315A/en unknown
- 2010-12-06 JP JP2012543183A patent/JP5714024B2/ja active Active
- 2010-12-06 WO PCT/US2010/059108 patent/WO2011071821A1/en not_active Ceased
- 2010-12-06 CN CN201911273119.5A patent/CN111100078A/zh active Pending
- 2010-12-06 SI SI201031119A patent/SI2509963T1/sl unknown
- 2010-12-06 SG SG10201408063SA patent/SG10201408063SA/en unknown
- 2010-12-06 BR BR112012013784-0A patent/BR112012013784B1/pt active IP Right Grant
- 2010-12-06 DK DK10788479.3T patent/DK2509963T3/en active
- 2010-12-06 TW TW099142438A patent/TWI526440B/zh active
- 2010-12-06 PH PH12014502593A patent/PH12014502593A1/en unknown
- 2010-12-06 PL PL10788479T patent/PL2509963T3/pl unknown
- 2010-12-06 NZ NZ600070A patent/NZ600070A/en unknown
- 2010-12-06 CA CA2781431A patent/CA2781431C/en active Active
- 2010-12-06 CN CN2010800550783A patent/CN102639510A/zh active Pending
- 2010-12-06 PH PH1/2012/501146A patent/PH12012501146A1/en unknown
- 2010-12-06 CN CN201911272657.2A patent/CN111100077A/zh active Pending
- 2010-12-06 PE PE2012000772A patent/PE20121499A1/es active IP Right Grant
- 2010-12-06 US US13/514,308 patent/US9067896B2/en active Active
- 2010-12-06 HU HUE10788479A patent/HUE026983T2/en unknown
-
2012
- 2012-05-17 ZA ZA2012/03612A patent/ZA201203612B/en unknown
- 2012-05-24 IL IL220012A patent/IL220012B/en active IP Right Grant
- 2012-05-25 TN TNP2012000263A patent/TN2012000263A1/en unknown
- 2012-06-06 CL CL2012001480A patent/CL2012001480A1/es unknown
- 2012-06-07 GT GT201200181A patent/GT201200181A/es unknown
- 2012-06-26 MA MA35005A patent/MA33849B1/fr unknown
- 2012-07-05 EC ECSP12012026 patent/ECSP12012026A/es unknown
-
2015
- 2015-01-20 JP JP2015008550A patent/JP6019142B2/ja active Active
-
2019
- 2019-01-07 AR ARP190100029A patent/AR114946A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160126T1 (hr) | Kristalinični oblici 3-(2,6-diklor-3,5-dimetoksi-fenil)-1-{6-[4-(4-etilpiperazin-1-il)-fenilamino]-pirimidin-4-il}-1-metil-ureje i njihove soli | |
| CY2021008I2 (el) | Πυριμιδινες οι οποιες παρεμποδιζουν την ανατυπωση ηιv | |
| FIC20250037I1 (fi) | Klaskoteroni ja sen kiteiset muodot | |
| BRPI0907915A2 (pt) | Piridinonas e piridazinonas | |
| BRPI0907435A2 (pt) | Derivados de 5-flúor pirimidina | |
| DK2154967T3 (da) | Pyrimidinderivater | |
| BRPI0922095A2 (pt) | derivados de piridina e pirimidina como inibidores de fosfodiesterase 10 | |
| ATE548355T1 (de) | 4- (4-cyano-2-thioaryl) -dihydropyrimidinone und ihre verwendung | |
| BRPI0921598A2 (pt) | derivados de piridina e pirimidina como inibidores de fosfodiesterase 10 | |
| DK2185693T3 (da) | Differentiering af humane embryoniske stamceller | |
| BRPI0815440A2 (pt) | 5-substituidos 2- (alcoximetil) furanos | |
| ATE489389T1 (de) | 2 -heteroaryl- pyrrolo ä3, 4-cüpyrrol- derivate und deren verwendung als scd inhibitoren | |
| DK2140072T3 (da) | Afløb med justeringsramme | |
| BRPI0920496A2 (pt) | derivados substituídos de pirimidina etriazina | |
| BRPI1012198A2 (pt) | sais de dissacarina, ácido difumárico, ácido di-1-hidróxi-2-naftoico e ácido mono-benzoico de 2-(4-((2-amino-4-metil-6-(pentilamino) pirimidin-5-il)metil) fenil) acetato de 4-(dimetilamino)butila | |
| BRPI1014039A2 (pt) | 6-(3-aza-biciclo[3.1.0]hex-3-il)-2-fenil-pirimidinas | |
| DK2280962T5 (da) | Pyridazinonderivater | |
| IL220440B (en) | Laser daylight designation and pointing | |
| BRPI0916679A2 (pt) | 5-alquinil-pirimidinas | |
| FI20075934L (fi) | Termotela | |
| CU20090141A7 (es) | Compuestos 2-amino pirimidina | |
| BRPI0820133A2 (pt) | Epg em linha | |
| BRPI0811115A2 (pt) | Compostos de heteroarilamida pirimidona | |
| BRPI0809971A2 (pt) | Derivados de piridina e pirimidina como antagosnistas de mglur2 | |
| DK2307397T3 (da) | 6-substituerede phenoxychroman-carboxylsyrederivater |